# Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

> **NCT02342704** · PHASE4 · TERMINATED · sponsor: **Biogen** · enrollment: 111 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** natalizumab
- **DRUG:** fingolimod

## Key facts

- **NCT ID:** NCT02342704
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-30
- **Primary completion:** 2016-05-18
- **Final completion:** 2016-05-18
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342704, "Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02342704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*